Testosterone Undecanoate May Reduce CV Morbidity

Long-term treatment with testosterone undecanoate was associated with reduced cardiovascular (CV) morbidity and mortality in patients with hypogonadism and type 2 diabetes, according to study results presented at the American Diabetes Association 79th Scientific Sessions, held June 7 to 11, 2019, in San Francisco, California.Testosterone decanoate Uses

As there is controversy regarding the CV effects of testosterone treatment, the investigators aimed to assess the morbidity and mortality rates associated with testosterone undecanoate treatment in men with hypogonadism and type 2 diabetes.

The researchers identified 823 men with hypogonadism, including 324 (39%) with type 2 diabetes. Of these, 152 received testosterone undecanoate 1000 mg/12 weeks (intervention group: mean age, 61.8 ± 5.1 years; mean follow-up, 7.4 years) and 172 declined treatment (control group: mean age, 63.6 ± 4.9 years; mean follow-up, 8.3 years).

In the intervention group, 54 patients (35.5%) had a preexisting CV disease (myocardial infarction, stroke, or diagnosis of carotid artery disease), as did 68 patients (39.5%; P =.4574) in the control group.Smoking rates were similar in both groups (42.1% and 38.4% for intervention vs control, respectively; P =.4939) and there was no difference in high-density lipoprotein levels. However, the other classical CV risk factors were more common in the intervention group, including higher body mass index (36.4 ± 4.5 kg/m2 vs 33.3 ± 5.3 kg/m2), systolic blood pressure (162.6 ± 13.1 mm Hg vs 145.4 ± 14.7 mm Hg), diastolic blood pressure (97.2 ± 10.7 mm Hg vs 84.7 ± 10.3 mm Hg), and low-density lipoprotein (4.6 ± 0.7 mmol/L vs 4.0 ± 1.4 mmol/L) compared with the control group.

Views: 3


You need to be a member of Recampus to add comments!

Join Recampus

© 2021   Created by Aprendiendo Real Estate.   Powered by

Badges  |  Report an Issue  |  Terms of Service